Airbus Posts Solid Second Quarter as It Prepares to Significantly Ramp Production

Business Strategy & Outlook

Airbus primarily generates revenue through manufacturing commercial aircraft. It benefits immensely from being in a duopoly with Boeing in the commercial aircraft manufacturing business for aircraft 130 seats and up; the companies act as a funnel through which all commercial aircraft demand must flow. This allows both companies to actively manage their order backlogs to reduce cyclicality, despite the intense cyclicality of the customer base. Airbus’ commercial aircraft segment can broadly be split into two parts: nimble narrow-bodied planes that are ideal for efficiently running high-frequency short-haul routes, and wide-bodied behemoths that are generally reserved for transcontinental flights. Recently, narrow-body volume has increased substantially due to the global rise of low-cost carriers and improved technology that allows smaller airplanes to operate flight paths that were previously unprofitable.

Domestic flights have recovered from the pandemic much more quickly than international flights as well, so airlines are more comfortable ordering small aircraft rather than large. Critically, Airbus does not have much competition in the high end of the narrow-body market. This aircraft will enable fleet growth and may replace many aging midsize aircraft. On the wide-body side of the market, there’s a much slower growth, as expected improving technology will allow airlines to substitute narrow bodies for wide bodies for an increasing number of routes. Airbus has a competitive wide-body offering, the A350, though backlogs suggest that Boeing’s comparable 777, 777X, and 787 offerings resonate more with customers. Airbus also has segments dedicated to the production of defense-specific products and helicopter manufacturing. These businesses are less material to Airbus as a whole, generating slightly over 10% of midcycle EBIT. The modest growth from these segments, largely assuming that defense spending as a proportion of gross domestic product remains constant in the European Union and that helicopter deliveries rebound over the medium term.

Financial Strengths

The Airbus is well capitalized. The company ended the year with significant liquidity and is producing positive cash flow despite the distressed market. Vaccinations have encouraged domestic travel resumption in the developed world. Morningstar anticipates that the COVID-19 vaccine will be broadly distributed in the emerging world by 2022, which will allow a robust rebound in commercial air traffic. One does not think liquidity is a concern for Airbus, as the operating environment will improve markedly in the coming quarters and the company is already generating free cash flow. The company ended 2021 in a net cash position. Forward EBITDA covers forward interest expense many times, suggesting that interest obligations are easily covered. Airbus has a sizable pension obligation, but this will be manageable. The Airbus could access the capital markets, if necessary, given it has produced free cash flow during a travel shock. In March 2020, Airbus secured access to a EUR 15 billion line of credit, which supports this thesis. Given Airbus’ massive backlog, proven relationships with customers, and minimal debt burden, one doesn’t think there is a material possibility of financial distress over the forecast period. In March 2020, Airbus suspended its dividend to conserve liquidity as the coronavirus crisis shook the aviation industry. Airbus proposed a dividend during the fourth-quarter 2021 earnings review to be paid out in 2022, and it will grow its dividend with increased earnings per share.

Bulls Say

Airbus’ A320 family continues to have a substantial lead in the valuable narrow-body market, and the A321XLR has the potential to open new long-range routes to low-cost carriers.
Airbus is well positioned to benefit from emerging market growth in revenue passenger kilometers and a robust developed-market replacement cycle.
The commercial airframe manufacturing for aircraft 130 seats and up will remain a duopoly over the foreseeable future. The customers will not have many options other than continuing to rely on incumbents.

Company Description

Airbus is a major aerospace and defense firm. The company designs, develops, and manufactures commercial and military aircraft, as well as space launch vehicles and satellites. The company operates its business through three divisions: commercial, defense and space, and helicopters. Commercial offers a full range of aircraft ranging from the narrow-body (130-200 seats) A320 series to the much larger A350-1000 wide body. The defense and space segment supplies governments with military hardware, including transport aircraft, aerial tankers, and fighter aircraft (Eurofighter). The helicopter division manufactures turbine helicopters for the civil and parapublic markets.

(Source: Morningstar)

DISCLAIMER for General Advice: (This document is for general advice only).

This document is provided by Laverne Securities Pty Ltd T/as Laverne Investing. Laverne Securities Pty Ltd, CAR 001269781 of Laverne Capital Pty Ltd AFSL No. 482937.

The material in this document may contain general advice or recommendations which, while believed to be accurate at the time of publication, are not appropriate for all persons or accounts. This document does not purport to contain all the information that a prospective investor may require. The material contained in this document does not take into consideration an investor’s objectives, financial situation or needs. Before acting on the advice, investors should consider the appropriateness of the advice, having regard to the investor’s objectives, financial situation, and needs. The material contained in this document is for sales purposes. The material contained in this document is for information purposes only and is not an offer, solicitation or recommendation with respect to the subscription for, purchase or sale of securities or financial products and neither or anything in it shall form the basis of any contract or commitment. This document should not be regarded by recipients as a substitute for the exercise of their own judgment and recipients should seek independent advice.

The material in this document has been obtained from sources believed to be true but neither Laverne and Banyan Tree nor its associates make any recommendation or warranty concerning the accuracy or reliability or completeness of the information or the performance of the companies referred to in this document. Past performance is not indicative of future performance. Any opinions and or recommendations expressed in this material are subject to change without notice and, Laverne and Banyan Tree are not under any obligation to update or keep current the information contained herein. References made to third parties are based on information believed to be reliable but are not guaranteed as being accurate.

Laverne and Banyan Tree and its respective officers may have an interest in the securities or derivatives of any entities referred to in this material. Laverne and Banyan Tree do and seek to do business with companies that are the subject of its research reports. The analyst(s) hereby certify that all the views expressed in this report accurately reflect their personal views about the subject investment theme and/or company securities.

Although every attempt has been made to verify the accuracy of the information contained in the document, liability for any errors or omissions (except any statutory liability which cannot be excluded) is specifically excluded by Laverne and Banyan Tree, its associates, officers, directors, employees, and agents. Except for any liability which cannot be excluded, Laverne and Banyan Tree, its directors, employees and agents accept no liability or responsibility for any loss or damage of any kind, direct or indirect, arising out of the use of all or any part of this material. Recipients of this document agree in advance that Laverne and Banyan Tree are not liable to recipients in any matters whatsoever otherwise; recipients should disregard, destroy or delete this document. All information is correct at the time of publication. Laverne and Banyan Tree do not guarantee reliability and accuracy of the material contained in this document and are not liable for any unintentional errors in the document.

The securities of any company(ies) mentioned in this document may not be eligible for sale in all jurisdictions or to all categories of investors. This document is provided to the recipient only and is not to be distributed to third parties without the prior consent of Laverne and Banyan Tree.